QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study For MoxDuo(TM) IV Pain Therapy
QRxPharma Limited (Pink Sheets QRXPY; ASX QRX) announced the initiation of a Phase 2 comparative proofofconcept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the treatment of moderate to severe postoperative pain in patients following hip replacement surgery. Data from this study will serve [...]